Search Articles

View query in Help articles search

Search Results (1 to 6 of 6 Results)

Download search results: CSV END BibTex RIS


Effectiveness of Electronic Quality Improvement Activities to Reduce Cardiovascular Disease Risk in People With Chronic Kidney Disease in General Practice: Cluster Randomized Trial With Active Control

Effectiveness of Electronic Quality Improvement Activities to Reduce Cardiovascular Disease Risk in People With Chronic Kidney Disease in General Practice: Cluster Randomized Trial With Active Control

We determined that 2580 patients from 20 practices per group are required to detect an absolute 10% increase in the difference in the percentage of patients on optimal pharmacological management in the intervention group at 12 months postintervention compared with the control group at 80% power for a 2-sided 5% significance level.

Jo-Anne Manski-Nankervis, Barbara Hunter, Natalie Lumsden, Adrian Laughlin, Rita McMorrow, Douglas Boyle, Patty Chondros, Shilpanjali Jesudason, Jan Radford, Megan Prictor, Jon Emery, Paul Amores, An Tran-Duy, Craig Nelson

JMIR Form Res 2025;9:e54147

Combining mHealth Technology and Pharmacotherapy to Improve Mental Health Outcomes and Reduce Human Rights Abuses in West Africa: Intervention Field Trial

Combining mHealth Technology and Pharmacotherapy to Improve Mental Health Outcomes and Reduce Human Rights Abuses in West Africa: Intervention Field Trial

Findings from these collaborations have led us to develop M&M, a dual-pronged intervention involving (1) a smartphone-delivered mobile health treatment support toolkit (M-Healer app) designed to expose healers to brief psychosocial interventions, encourage them to preserve human rights in their practice, and prompt them to monitor the status of the people they serve, and (2) a visiting community nurse who provides pharmacological care directly to their patients at the prayer camp (Mobile Nurse).

Dror Ben-Zeev, Anna Larsen, Dzifa A Attah, Kwadwo Obeng, Alexa Beaulieu, Seth M Asafo, Jonathan Kuma Gavi, Arya Kadakia, Emmanuel Quame Sottie, Sammy Ohene, Lola Kola, Kevin Hallgren, Jaime Snyder, Pamela Y Collins, Angela Ofori-Atta, M-Healer Research Team

JMIR Ment Health 2024;11:e53096

Treatments for Primary Delusional Infestation: Systematic Review

Treatments for Primary Delusional Infestation: Systematic Review

Both of these reviews restricted their search strategy to antipsychotics; however, other pharmacological agents may also prove effective in treating delusional infestation. As such, we conducted a systematic review to identify pharmacological treatments used for primary delusional infestation to better understand their effectiveness and establish recommendations for the management of primary delusional infestation. The protocol was registered on PROSPERO (CRD42020198161).

Justin Di Lu, Ryan D Gotesman, Shawn Varghese, Patrick Fleming, Charles W Lynde

JMIR Dermatol 2022;5(1):e34323

Impact of Chronic Use of Antimalarials on SARS-CoV-2 Infection in Patients With Immune-Mediated Rheumatic Diseases: Protocol for a Multicentric Observational Cohort Study

Impact of Chronic Use of Antimalarials on SARS-CoV-2 Infection in Patients With Immune-Mediated Rheumatic Diseases: Protocol for a Multicentric Observational Cohort Study

Considering there is no specific, effective pharmacological treatment for COVID-19, several drugs have been tested, such as antivirals (lopinavir-ritonavir, remdesivir, favipiravir); antimalarials alone or combined with azithromycine; interleukin 6 (IL-6) antagonists; Janus kinase inhibitors and interferon, as well as other procedures (extracorporeal membrane oxygenation and convalescent plasma).

Ana Gomides, Gilda Ferreira, Adriana Kakehasi, Marcus Lacerda, Cláudia Marques, Licia Mota, Eduardo Paiva, Gecilmara Pileggi, José Provenza, Edgard Reis-Neto, Vanderson Sampaio, Ricardo Xavier, Marcelo Pinheiro

JMIR Res Protoc 2020;9(10):e23532